Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial.
Timothy J WhelanKeying XuJenna WongGregory Russell PondYi ZhangMelanie SpearsRanelle SalungaElizabeth MallonKaren J TaylorAnnette HasenburgMarkopoulos ChristosLuc DirixCornelis J H van de VeldeDaniel W ReaCatherine A SchnabelKai TreunerJane BayaniPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.